Full-year 2026 product bookings are expected to be weighted toward the back half of the year due to the timing of the Titan ...

Non-GAAP EBITDA for the first quarter 2026 totaled $45 million compared with $24 million a year ago. Our strong profitability performance in the first quarter reflects disciplined cost management and ...

Omnicell () has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks. Unlock hedge fund-level data and powerful investing tools for smart ...

Q1 2026. Management View "We started 2026 with solid execution in the first quarter, delivering results at the high end or above our previo ...

Thank you for standing by. My name is Tina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Omnicell First Quarter 2026 Financial Results Call.

Omnicell delivers strong first quarter 2026 financial results Raises full year 2026 non-GAAP EBITDA and non-GAAP EPS guidance ...

View source version on businesswire.com: https://www.businesswire.com/news/home/20260428485116/en/ The articles, information, and content displayed on this webpage ...

Healthcare tech company Omnicell (NASDAQ:OMCL) reported Q1 CY2026 results , with sales up 14.9% year on year to $309.9 ...

SUSE ®, a global leader of enterprise open source solutions, today announced the winners of the 2026 SUSE Customer Awards at ...

In this context, Oncotelic Therapeutics reflects a broader strategic alignment with regulatory-driven innovation. As the industry increasingly prioritizes automation and data integrity, companies ...

AUSTIN, Texas, April 07, 2026 (GLOBE NEWSWIRE) -- AINewsWire Editorial Coverage: As regulatory expectations intensify and manufacturing complexity grows, pharmaceutical companies are moving beyond ...